Office for Technology Development The University of Texas Southwestern Medical Center at Dallas

Mission

The mission of the Office for Technology Development is to ethically and effectively develop and commercialize intellectual property created at UT Southwestern, thereby generating income for UT Southwestern and benefiting researchers, patients, and the community at large.

Goals

The goals of the Office for Technology Development are to serve the faculty, advance new technologies and therapies for the benefit of society, generate income for stakeholders and develop regional biotechnology companies.

Overview

UT Southwestern Medical Center has been protecting and licensing intellectual property for over 25 years. Prior to 1999, technology transfer activities at UT Southwestern were conducted by the Office for Legal Affairs. In 1999, a separate entity, the Office for Technology Development (OTD), was created to manage UT Southwestern's activities in this area and to facilitate the formation of biotechnology companies based on UT Southwestern-developed technologies. The staff of the OTD has since been increased from 6 to 22 individuals, who are now organized within three divisions: Technology Transfer (licensing and cooperative research), Venture Development, and Portfolio Management. Many of the new professional staff within the OTD have been recruited from the biopharmaceutical industry to create a pro-active, business-oriented culture and to thereby promote relationships with commercial partners. Since its formation in 1999, the OTD has increased its cumulative license revenues from over \$21 million to over \$110 million and has helped create several UT Southwestern start-up companies that have collectively raised over \$200 million in financing.

The Office for Technology Development is actively developing <u>BioCenter at Southwestern Medical District</u>, a 15.5 acre biomedical business campus at UT Southwestern to facilitate the location and growth of the biomedical industry in Dallas. The first building (\$53 million, 110,000 sq. ft.) will open in July 2009. BioCenter will attract mature companies and early stage companies wishing to be associated with the university, and will greatly stimulate the creation of new biomedical companies founded to commercialize technologies arising at UT Southwestern. The Office for Technology Development looks forward to major growth of the biomedical industry in Dallas.

Dr. Stone joined the Office for Technology Development in August, 1998, as the Vice President for Technology Development. He directs licensing operations as well as the biotechnology development initiative taking place at the University of Texas Southwestern Medical Center at Dallas and is a liaison with pharmaceutical and biotechnology companies interested in partnership with UT Southwestern scientists. In addition to his role in this office, he is also a professor of internal medicine, physiology, and biochemistry, and is also the holder of the NCH Corporation Chair in Molecular Transport. His research focuses on the molecular analysis of proton pumps that are involved in renal acidification, osteoporosis, and cancer. In his role as Vice President for Technology, Dr. Stone and his team have increased annual revenues from \$3.5 million to \$12 million. In addition, the Office for Technology Development has launched six start-up biotechnology companies that collectively have raised over \$200 million in Dr. Stone has served on the board of directors of Eliance venture financing. Biotechnology, Inc., MacroGenics, Inc., and Reata Pharmaceuticals, Inc. In addition, he served as the chairman of the U.T. Regents' Technology Transfer Commission and is a member of the board of the Texas Emerging Technology Fund's Life Science Commercialization Center. Dr. Stone is member of STARTech Early Venture's Mentor Program, and is the recipient of the Metroplex Technology Business Council' Technology Titan Award. Dr. Stone received his undergraduate training in the Plan II Program at The University of Texas at Austin. After completion of medical school at UT Southwestern Medical Center at Dallas, he received his housestaff training in internal medicine at Columbia Presbyterian Medical Center in New York City. Subsequently, he completed clinical and research fellowship training in Nephrology at UT Southwestern and Cornell University in Ithaca, NY and in 1984, joined the faculty at UT-Southwestern. He has been the recipient of a Searle Scholarship and Established Investigator of the American Heart Association, and is a member of the American Society for Clinical Investigation and the Association of American Physicians.